MedPath

Terlipressin

Generic Name
Terlipressin
Brand Names
Terlivaz
Drug Type
Biotech
CAS Number
14636-12-5
Unique Ingredient Identifier
7Z5X49W53P
Background

Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.

Indication

Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.

Associated Conditions
Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
Clinical Trials
Related News

BioVie Initiates Phase 2 Trial of Bezisterim for Long COVID Neurological Symptoms

• BioVie has enrolled the first patient in its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms of long COVID, with topline data expected in the first half of 2026. • Long COVID affects approximately 20 million adults in the US alone, with 10-30% of COVID-19 patients experiencing persistent symptoms including fatigue and cognitive impairment, yet no FDA-approved treatments exist. • Bezisterim targets neuroinflammation by modulating NF-κB activation and TNF-α production, pathways implicated in both long COVID and neurodegenerative diseases like Alzheimer's and Parkinson's.

Mallinckrodt to Present Five Clinical Studies on TERLIVAZ for Hepatorenal Syndrome at DDW 2025

• Mallinckrodt will present five clinical analyses of TERLIVAZ (terlipressin) for hepatorenal syndrome with rapid reduction in kidney function (HRS-AKI) at Digestive Disease Week 2025 in San Diego. • TERLIVAZ is the first and only FDA-approved treatment for improving kidney function in adults with HRS-AKI, a rare and life-threatening condition affecting approximately 42,000 Americans annually. • The presentations will include real-world evidence on treatment outcomes in various patient populations, including those on transplant waitlists and with alcohol-associated liver disease.

BioVie Launches SUNRISE-PD Trial to Test Novel Anti-inflammatory Approach for Early Parkinson's Disease

• BioVie has enrolled the first patient in its Phase 2 SUNRISE-PD trial evaluating bezisterim, an anti-inflammatory and insulin-sensitizing drug candidate, in early-stage Parkinson's disease patients who haven't received carbidopa/levodopa treatment. • The innovative trial features a hybrid decentralized design allowing patients to participate remotely from home, with support from major foundations including The Michael J. Fox Foundation, potentially expanding access to clinical research. • Bezisterim targets underlying inflammation and insulin resistance mechanisms implicated in Parkinson's disease progression, offering a potential alternative to traditional dopamine-replacement therapies that only provide symptomatic relief.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy